Stocks · News reference

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

Sep 8, 2026, 3:47 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 8, 2026, 3:47 PM
Checked: Sep 8, 2026, 3:47 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 2, 2026, 1:28 PMBenzinga Newsdesk
Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA Nephropathy
VERA
BenzingaSep 17, 2026, 3:58 PMAvi Kapoor
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
ABSI ARM GNRC HPE INTC
BenzingaSep 15, 2026, 4:28 PMVandana Singh
What's Going on With Vera Therapeutics Stock on Tuesday?
Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progression in IgA nephropathy.
VERA
BenzingaSep 15, 2026, 12:55 PMBenzinga Newsdesk
Vera Therapeutics shares are trading higher after the company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression.
VERA